GlassScriptPhysician profile
Stephen M Damiani
NPI 1609820950
$11,627.18
in general payments reported to CMS, 2019-2025
43 companies · $2,570 in 2025
The $2,570 reported for 2025 was more than what 81% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $738 · 2020: $987 · 2021: $1,565 · 2022: $1,625 · 2023: $2,143 · 2024: $1,999 · 2025: $2,570.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,653 · Gift: $59.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,652.95 |
| Gift | $59.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,245.48 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Insulet Corporation | $1,684.66 | 2019-2025 | Omnipod |
| Dexcom, INC. | $1,245.37 | 2021-2025 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $1,134.70 | 2019-2025 | Ozempic, Rybelsus, Sogroya |
| Corcept Therapeutics | $871.20 | 2019-2025 | Korlym |
| Medtronic, INC. | $794.67 | 2021-2025 | Minimed 780g |
| Recordati_rare_diseases_inc. | $363.47 | 2020-2025 | Isturisa, Signifor Lar |
| Abbvie INC. | $351.05 | 2019-2025 | |
| Lilly USA, LLC | $279.63 | 2020-2025 | Mounjaro, Jardiance, Lyumjev |
| Mannkind Corporation | $241.43 | 2019-2023 | Afrezza |
| Tandem Diabetes Care, INC. | $239.34 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Xeris Pharmaceuticals, INC. | $194.97 | 2022-2025 | Gvoke Hypopen, Recorlev |
| Kyowa Kirin, INC. | $176.18 | 2023-2025 | Crysvita |
| Ascendis Pharma Endocrinology INC | $160.92 | 2024-2025 | Yorvipath |
| Sanofi-Aventis U.S. LLC | $139.17 | 2019-2024 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Damiani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.